Arrowhead Research said this week that it has appointed Larry Stambaugh as president and CEO of its Calando Pharmaceuticals and Insert Therapeutics subsidiaries, which are expected to be merged.
Calando is developing RNAi-based treatments for cancer (see RNAi News, 3/22/2007). Insert is focused on developing a proprietary delivery system for small molecule- and nucleic acid-based cancer drugs.
Stambaugh will replace John Petrovich, who has been serving as the CEO of both Calando and Insert, will remain as executive vice president of both companies and of the combined company when the merger is completed.
Stambaugh was previously the chairman and CEO of Maxim Pharmaceuticals. He holds a BBA from Washburn University and is a certified public accountant, Arrowhead said.
Antisense drug developer Genta said that Betsy McCaughey has resigned from the company’s board.
She served on Genta’s board since 2001.